Page 6 - Laurus Labs

Laurus Labs surges 50% in one month on growth prospects in US market

The stock hit a 52-week high of Rs 494, up 9 per cent on the BSE on Wednesday, surging 20 per cent in past two trading days on expectation of strong growth prospects in United States.

Patent for Pharmacyclic's cancer drug revoked on challenge by Laurus Labs

Patent Office rules that the drug isn't an improvement over other formulations in the same space, hence not eligible to enjoy a patent

Laurus Labs launches generic Lyrica in US to treat neuropathic conditions

Market size in the US for the API was about $5,497 million in FY19; firm says generic launch is one of its largest this year

Laurus gets USFDA nod for drug that treats malaria, auto-immune disease

Medicine is a therapeutic equivalent of Plaquenil tablets of Concordia Pharma of US

Laurus Labs hits record low on disappointing Q1 results

The stock slipped 8% to Rs 430 on the BSE in intra-day trade after the company reported 57% year-on-year decline in net profit at Rs 166 million in June quarter.

Laurus Labs gets USFDA nod for Visakhapatnam unit

The firm is one of the leading manufacturers of APIs for anti-retroviral (ARV), Hepatitis C, and Oncology

Laurus Labs Q1 net up 51% at Rs 39 cr

Total revenue grew 16.7% to Rs 478.4 cr

Laurus Labs lists at Rs 490, 14% premium against its issue price

On the NSE, the stock listed at Rs 489.90 and gained as much as Rs 498

Laurus Lab set for stock trading debut from Monday

The IPO, which opened to public subscription on December 6-8, was subscribed 4.54 times at a price band of Rs 426-428 per share

Laurus Labs' IPO sails through, subscribed 4.5 times

The Rs 1,332-cr IPO received bids for over 9.87 crore shares as against the total issue size of over 2.19 crore scrips

Laurus Labs sets IPO price band at Rs 426-428 per share

The firm proposes to use the net proceeds from the fresh issue towards pre-payment of term loans